Key facts
- ClearFlow’s last known valuation is $80.5M (Aug 2020).
- It has raised $52.4M across 7 recorded rounds; the latest was Seed Round ($2.1M) in Jul 2025.
- Notable investors include Albany Capital (Australia), Aphelion Capital, Bend Venture Conference, California Technology Ventures, Global Cardiovascular Innovation Center — 10 tracked in total.
- ClearFlow has filed 8 Form Ds with the SEC since 2014, most recently Aug 2025 ($2.1M sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 7 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for ClearFlow
Funding rounds
7 roundsAbout ClearFlow
Developer of the active clearance technology medical device designed to revolutionize the recovery process for patients following cardiothoracic surgery. The company's device helps maintain chest-drain patency after surgery, reducing the incidence of retained blood and fluids thereby decreasing the risk of post-surgical interventions and complications related to retained blood syndrome, providing patients with a method that advances healing by preventing post-operative complications associated with retained blood and fluid.
- Sector
- Healthcare
- HQ
- Irvine, CA, United States
- Founded
- 2006
- Employees
- 25
- Website
- clearflow.com/
- Ownership
- Privately Held (backing)
ClearFlow doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ClearFlow shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ClearFlow in its N-PORT filings yet. We sweep new filings monthly.